Literature DB >> 34571324

On the cusp of cures: Breakthroughs in Batten disease research.

Jon J Brudvig1, Jill M Weimer2.   

Abstract

Batten disease is a family of rare, lysosomal disorders caused by mutations in one of at least 13 genes, which encode a diverse set of lysosomal and extralysosomal proteins. Despite decades of research, the development of effective therapies has remained intractable. But now, the field is experiencing rapid, unprecedented progress on multiple fronts. New tools are providing insights into previously unsolvable problems, with molecular functions now known for nine Batten disease proteins. Protein interactome data are uncovering potential functional overlap between several Batten disease proteins, providing long-sought links between seemingly disparate proteins. Understanding of cellular etiology is elucidating contributions from and interactions between various CNS cell types. Collectively, this explosion in insight is hastening an unparalleled period of therapeutic breakthroughs, with multiple therapies showing great promise in preclinical and clinical studies. The coming years will provide a continuation of this rapid progress, with the promise of effective treatments giving patients hope.
Copyright © 2021. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2021        PMID: 34571324     DOI: 10.1016/j.conb.2021.08.003

Source DB:  PubMed          Journal:  Curr Opin Neurobiol        ISSN: 0959-4388            Impact factor:   6.627


  4 in total

1.  Clinical and genetic characterization of a cohort of 97 CLN6 patients tested at a single center.

Authors:  Corina-Marcela Rus; Thomas Weissensteiner; Catarina Pereira; Iuliana Susnea; Bright D Danquah; Galina Morales Torres; Maria Eugenia Rocha; Claudia Cozma; Deepa Saravanakumar; Sumanth Mannepalli; Krishna K Kandaswamy; Sebastiano Di Bucchianico; Ralf Zimmermann; Arndt Rolfs; Peter Bauer; Christian Beetz
Journal:  Orphanet J Rare Dis       Date:  2022-05-03       Impact factor: 4.303

Review 2.  Current Advances in RNA Therapeutics for Human Diseases.

Authors:  Hannah Zogg; Rajan Singh; Seungil Ro
Journal:  Int J Mol Sci       Date:  2022-03-01       Impact factor: 5.923

3.  CLN7 gene therapy: hope for an ultra-rare condition.

Authors:  Jon J Brudvig; Jill M Weimer
Journal:  J Clin Invest       Date:  2022-03-01       Impact factor: 14.808

4.  Glycerophosphoinositol is Elevated in Blood Samples From CLN3 Δex7-8 pigs, Cln3 Δex7-8 Mice, and CLN3-Affected Individuals.

Authors:  Jon J Brudvig; Vicki J Swier; Tyler B Johnson; Jacob C Cain; Melissa Pratt; Mitch Rechtzigel; Hannah Leppert; An N Dang Do; Forbes D Porter; Jill M Weimer
Journal:  Biomark Insights       Date:  2022-06-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.